Commodore Capital’s Mereo BioPharma MREO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q2
Sell
-1,954,970
Closed -$2.19M 27
2022
Q1
$2.19M Hold
1,954,970
0.49% 27
2021
Q4
$3.13M Sell
1,954,970
-17,988
-0.9% -$36K 0.72% 23
2021
Q3
$4.78M Sell
1,972,958
-86,771
-4% -$230K 1.26% 24
2021
Q2
$6.53M Buy
2,059,729
+10,972
+0.5% +$36.8K 2.27% 18
2021
Q1
$6.9M Buy
2,048,757
+194,479
+10% +$687K 2.75% 17
2020
Q4
$6.64M Buy
+1,854,278
New +$4.64M 3.61% 14

Other funds holding MREO

Commodore Capital's MREO Position: Q2 2022 in Review

Commodore Capital sold out of Mereo BioPharma (MREO) in Q2 2022, closing a stake of 1,954,970 shares — an estimated $2.19M sold.

Commodore Capital first reported a position in MREO in Q4 2020 and held it in 6 quarters. The position peaked at $6.9M in Q1 2021. 64 funds tracked by Wall St. Rank hold MREO as of Q2 2022.

  • Commodore Capital reported no remaining Mereo BioPharma position as of Q2 2022 after selling out during the quarter.
  • Commodore Capital sold 1,954,970 Mereo BioPharma shares in Q2 2022, an estimated $2.19M.
  • Commodore Capital first reported a position in Mereo BioPharma in Q4 2020 and held it in 6 quarters.
  • Commodore Capital's Mereo BioPharma position peaked at $6.9M in Q1 2021.
  • 64 funds tracked by Wall St. Rank held Mereo BioPharma as of Q2 2022.

Based on Commodore Capital's 13F filing for Q2 2022, filed 15 Aug 2022.